Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
NCT05840835
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
DRUG:
IMX-110 combined with Tislelizumab
Sponsor
Immix Biopharma, Inc.
Collaborators
[object Object]
[object Object]